Epidarex Portfolio News

24 Aug

28

Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

In All, Portfolio

Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that its complement C3 inhibitor, APL-2, met…

22 Aug

26

Topas Therapeutics Signs Multi-Year Research and Option Agreement with Lilly Focused on Immune Tolerance

In All, Portfolio

Work will utilize Topas’ novel approach for antigen-specific tolerance induction Lilly has option to in-license and further develop drug candidates produced under the collaboration   Hamburg, Germany, August 22, 2017 – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private company, today announced that it has…

10 Aug

25

Apellis Pharmaceuticals Announces $60 Million Series E Financing

In All, Portfolio

Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria. Louisville, Kentucky, August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred…

10 Aug

45

Epidarex Capital Portfolio Company, Confluence Life Sciences, Acquired by Aclaris Therapeutics

In All, Portfolio

August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with the sale of Confluence Life Sciences, Inc. (“Confluence”) to Aclaris Therapeutics, Inc. (NASDAQ: ACRS) for a total deal value of…

08 Aug

24

Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.

In All, Portfolio

Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in…

29 Jun

40

Positive Data from APL-2 Studies Show Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH

In All, Portfolio

Louisville, KY, June 29, 2017 – Apellis Pharmaceuticals, Inc. today provided an update on clinical outcomes in its two ongoing Phase 1b clinical trials with APL-2, a complement C3 inhibitor, in the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired,…

28 Jun

38

Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences

In All, Portfolio

Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital…

20 Jun

33

IGEM Therapeutics Completes Initial Closing of Series A Financing; Appoints CEO

In All, Portfolio

Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer IgE antibodies shown to offer greater efficacy than IgG comparator in cancer models Dr. Tim Wilson appointed Chief Executive Officer London, 20 June 2017 – IGEM Therapeutics (IGEM),…